Patients, caregivers to hear research on a potential treatment option for primary immune deficiency

1 Star2 Stars3 Stars4 Stars5 Stars (43 votes, average: 2.95 out of 5)
Loading...

Contact: Jennifer Scharpf
443-562-3517
Immune Deficiency Foundation

On site contact:Al Hinman
Al.Hinman@edelman.com
212-819-4855
917-657-5222 (onsite)
Edelman Health

What: The Third Immune Deficiency Foundation (IDF) National Conference, June 23-25, 2005, is the largest meeting bringing together patients, families and caregivers affected by Primary Immune Deficiency.

An important session at the IDF Conference on Friday June 24th is a symposium titled, “Subcutaneous Immune Globulin Therapy: A New Approach to Managing Primary Immune Deficiency Diseases in the United States.”

Leading Primary Immune Deficiency researcher Dr. Melvin Berger will lead the symposium. He will provide a patient-focused look at the latest research that shows how changing the way in which immune-restoring immune globulin therapy is administered could offer patients a needed, safe and effective alternative to the current approach to administering this therapy.

Dr. Berger, of Case Western Reserve University’s Rainbow Babies and Children’s Hospital, recently discussed his research at an FDA Workshop on “Intravenous Immune Globulins in the 21st Century.” Last year, “Clinical Immunology” published his paper on “Subcutaneous Immunoglobulin Replacement in Primary Immunodeficiencies.”

When/Where: Friday, June 24
7:00 – 8:30 AM ET
Disney’s Contemporary Resort
Fantasia H&J
Walt Disney World®, Orlando, FL